File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: High-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies

TitleHigh-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignancies
Authors
Issue Date2009
PublisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmt
Citation
Bone Marrow Transplantation, 2009, v. 44 n. 11, p. 709-714 How to Cite?
AbstractNatural killer (NK)-cell lymphomas are aggressive. Patients with early (stage I/II) diseases respond favorably to radiotherapy and chemotherapy. Patients with relapses and advanced (stage III/IV) diseases have poor outcome. To improve treatment results, high-dose chemotherapy with hematopoietic SCT (HSCT) has been performed. A review of 57 published cases of autologous HSCT showed the status pre-HSCT as the only significant prognostic factor. HSCT at CR had the best survival. As patients achieving CR with chemotherapy and radiotherapy also have favorable outcome, a definite advantage of autologous HSCT cannot be established. Patients with advanced, relapsed or refractory diseases had dismal survivals after autologous HSCT. Allogeneic HSCT had been reported in about 30 patients, with a 2-year OS of 40%. To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined. Furthermore, clinicopathological characteristics predicting benefits from allogeneic HSCT need to be determined. HSCT is a potential option in NK-cell lymphoma. However, autologous HSCT may not be necessary for good-risk patients in CR. Whether poor risk patients will have improved outcome with autologous HSCT remains to be defined. The role of allogeneic HSCT requires more rigorous future studies. © 2009 Macmillan Publishers Limited All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/125107
ISSN
2015 Impact Factor: 3.636
2015 SCImago Journal Rankings: 1.585
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-10-31T11:11:43Z-
dc.date.available2010-10-31T11:11:43Z-
dc.date.issued2009en_HK
dc.identifier.citationBone Marrow Transplantation, 2009, v. 44 n. 11, p. 709-714en_HK
dc.identifier.issn0268-3369en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125107-
dc.description.abstractNatural killer (NK)-cell lymphomas are aggressive. Patients with early (stage I/II) diseases respond favorably to radiotherapy and chemotherapy. Patients with relapses and advanced (stage III/IV) diseases have poor outcome. To improve treatment results, high-dose chemotherapy with hematopoietic SCT (HSCT) has been performed. A review of 57 published cases of autologous HSCT showed the status pre-HSCT as the only significant prognostic factor. HSCT at CR had the best survival. As patients achieving CR with chemotherapy and radiotherapy also have favorable outcome, a definite advantage of autologous HSCT cannot be established. Patients with advanced, relapsed or refractory diseases had dismal survivals after autologous HSCT. Allogeneic HSCT had been reported in about 30 patients, with a 2-year OS of 40%. To evaluate the efficacy of allogeneic HSCT, optimal conditioning regimens and a clear graft-versus-lymphoma effect should be defined. Furthermore, clinicopathological characteristics predicting benefits from allogeneic HSCT need to be determined. HSCT is a potential option in NK-cell lymphoma. However, autologous HSCT may not be necessary for good-risk patients in CR. Whether poor risk patients will have improved outcome with autologous HSCT remains to be defined. The role of allogeneic HSCT requires more rigorous future studies. © 2009 Macmillan Publishers Limited All rights reserved.en_HK
dc.languageengen_HK
dc.publisherNature Publishing Group. The Journal's web site is located at http://www.nature.com/bmten_HK
dc.relation.ispartofBone Marrow Transplantationen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshCombined Modality Therapyen_HK
dc.subject.meshDose-Response Relationship, Drugen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHematopoietic Stem Cell Transplantation - methodsen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLymphoma, Extranodal NK-T-Cell - drug therapy - pathology - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshSkin Neoplasms - drug therapy - therapyen_HK
dc.subject.meshTransplantation Conditioningen_HK
dc.subject.meshYoung Adulten_HK
dc.titleHigh-dose chemotherapy and hematopoietic SCT in the management of natural killer-cell malignanciesen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0268-3369&volume=44&spage=709–714&epage=&date=2009&atitle=High-dose+chemotherapy+and+hematopoietic+SCT+in+the+management+of+natural+killer-cell+malignanciesen_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1038/bmt.2009.239en_HK
dc.identifier.pmid19767784-
dc.identifier.scopuseid_2-s2.0-75049085234en_HK
dc.identifier.hkuros180774en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-75049085234&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume44en_HK
dc.identifier.issue11en_HK
dc.identifier.spage709en_HK
dc.identifier.epage714en_HK
dc.identifier.isiWOS:000272557200001-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.citeulike5815471-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats